Correction to Lancet Diabetes Endocrinol 2020; 8: 582-93

No authors listed

Published Erratum

No authors listed. Lancet Diabetes Endocrinol. 2020 Aug.

. 2020 Aug;8(8):e3.

doi: 10.1016/S2213-8587(20)30217-5. Epub 2020 Jun 25.

No abstract available

Erratum for

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.